Chris Williamson

AG1 NextGen was tested in four clinical trials, showing it improved key nutrient levels in 3 months and increased healthy gut bacteria tenfold.

"And they've taken it a step further with AG1 NextGen, backed by four clinical trials. In those trials it was shown to fill common nutrient gaps, improve key nutrient levels in just 3 months, and increase healthy gut bacteria by 10 times, even in people who already eat well." (said at 0:20:15)

The host's statement overstates the scientific body of evidence. Published research evaluating AG1 includes two small, manufacturer-funded randomized crossover/placebo-controlled human trials (PMID 41988471, n=20 for 2 weeks; PMID 39352252, n=30 for 4 weeks) and two in vitro gastrointestinal models (PMID 38248338, PMID 39065031), rather than four full clinical trials. While the 2-week crossover trial demonstrated that AG1 filled micronutrient gaps (such as vitamins A, C, and E) in trained adults who already ate well, neither published human trial lasted 3 months, nor did they show a tenfold increase in total healthy gut bacteria. Instead, the 4-week and 2-week trials observed selective enrichment of specific probiotic species (such as Bifidobacterium and Lactobacillus spp.) without global shifts in microbiome diversity.

• contradicts: AG1 ® Induces a Favorable Impact on Gut Microbial Structure and Functionality in the … (Current issues in molecular biology 2024) · cited 3x in the literature

  "We explored the effect of the novel foundational nutrition supplement AG1 ® on the composition of human microbiota in an in vitro experimental design. Employing the Simulator of Human Intestinal Microbial Ecosystem (SHIME ® ) model, AG1 ® underwent digestion, absorption, and subsequent colonic microenvironment simulation under physiologically relevant conditions in healthy human fecal inocula." (abstract, methods)

  pubmedfull study (doi)
• partial: The effects of AG1® supplementation on the gut microbiome of healthy adults: a random… (Journal of the International Society of Sports Nutrition 2024) · cited 5x in the literature

  "Using a double-blind, randomized, two-arm, placebo-controlled, parallel design, we examined a 4-week daily supplementation regimen of AG1 ® vs. placebo (PL)... AG1 ® supplementation enriched two probiotic taxa ( Lactobacillus acidophilus and Bifidobacterium bifidum ) that likely stem from the probiotics species that exist in the product, as well as L. lactis CH_LC01 and Acetatifactor sp900066565 ASM1486575v1 while reducing Clostridium sp000435835." (abstract, methods and results)

  pubmedfull study (doi)
• partial: Effect of AG1 ® supplementation on nutritional adequacy and gut microbial composition… (Frontiers in nutrition 2026)

  "AG1 ® did not produce large, global shifts in microbial alpha or beta diversity, supplementation was associated with selective enrichment of key bacterial taxa commonly linked to gut health, including Lactiplantibacillus plantarum, Lacticaseibacillus rhamnosus , and Bifidobacterium animalis . AG1 ® supplementation significantly improved nutritional adequacy by increasing the total number of micronutrient Estimated Average Requirements (EARs) met compared to placebo (2.8; p = 0.0011)... Vitamins A, C, and E were the most common nutrient gaps filled by AG1 supplementation." (abstract, results)

  pubmedfull study (doi)

In clinical trials, Timeline (urolithin A) increased mitochondrial renewal by over 40% in 16 weeks along with improvements in overall energy.

"In clinical trials, people saw mitochondrial renewal increased by more than 40% in just 16 weeks along with improvements in their overall energy." (said at 0:34:59)

Randomized placebo-controlled clinical trials of Urolithin A (Timeline / Mitopure) administered over 4 months (16 weeks) have evaluated biomarkers of mitophagy (mitochondrial recycling/renewal), muscle strength, endurance, and cellular metabolism. While trials observed increased expression of mitophagy-related proteins, reductions in plasma acylcarnitines, and modest improvements in muscle strength (~12%) or muscle endurance, primary functional endpoints (such as peak power output in middle-aged adults or maximal ATP production and 6-minute walk distance in older adults) did not achieve statistically significant improvements over placebo. Framing these biomarker changes as a definitive '>40% increase in mitochondrial renewal' and conflating them with direct improvements in 'overall energy' overstates the clinical findings.

• partial: Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Olde… (JAMA network open 2022) · cited 196x in the literature

  "Although the improvements in the 6-minute walk distance and maximal ATP production in the hand muscle were not significant in the urolithin A group vs the placebo group, long-term urolithin A supplementation was beneficial for muscle endurance and plasma biomarkers, suggesting that urolithin A may counteract age-associated muscle decline" (abstract, conclusions, passage verified)

  pubmedfull study (doi)
• partial: Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondria… (Cell reports. Medicine 2022) · cited 243x in the literature

  "We present results from a randomized, placebo-controlled trial in middle-aged adults where we administer a postbiotic compound Urolithin A (Mitopure), a known mitophagy activator, at two doses for 4 months (NCT03464500). The data show significant improvements in muscle strength (~12%) with intake of Urolithin A... but do not notice a significant improvement on peak power output (primary endpoint)." (abstract, results)

  pubmedfull study (doi)

Taking baby aspirin has been shown to offer cardiovascular benefits in people who have elevated levels of lipoprotein(a).

"there's a group of people, for example, where it does make sense to take baby aspirin. It's been shown that there can be benefits, and it's those people, just as an example, who have high levels of lipoprotein(a) or Lp(a)." (said at 1:05:40)

While observational cohort studies (such as MESA) and genetic subgroup analyses have suggested an association between aspirin use and reduced coronary heart disease or myocardial infarction events in individuals with elevated lipoprotein(a) or LPA variants, systematic reviews and meta-analyses have found no statistically significant reduction in overall major adverse cardiovascular events (MACE) and note that the overall certainty of evidence is very low. Dedicated randomized controlled trials are still lacking.

• supports: Aspirin and Cardiovascular Risk in Individuals With Elevated Lipoprotein(a): The Multi-Eth… (Journal of the American Heart Association 2024) · cited 75x in the literature

  "Aspirin was associated with a significant reduction in CHD events among those with elevated lipoprotein(a) (hazard ratio, 0.54 [95% CI, 0.32-0.94]; P =0.03)." (abstract, results, passage verified)

  pubmedfull study (doi)
• partial: Impact of Aspirin on Primary Prevention of Cardiovascular Events in Patients with Elevated… (American journal of cardiovascular drugs : drugs, devices, and other interventions 2026)

  "Aspirin was not associated with a reduction in MACE (HR 0.99, 95% CI 0.79-1.24; I 2 = 23%; four studies). MACE reduction was associated with aspirin in rs3798220-C carriers (HR 0.39, 95% CI 0.19-0.77, two studies). Aspirin was also associated with significant reduction of events regarding MI (HR 0.60, 95% CI 0.41-0.88, two studies) and cardiovascular mortality (HR 0.48, 95% CI 0.28-0.83, one study)... Overall certainty of evidence was very low." (abstract, results, passage verified)

  pubmedfull study (doi)
• contradicts: Efficacy and safety of aspirin for primary prevention in adults with elevated lipoprotein(… (European journal of preventive cardiology 2026) · cited 4x in the literature

  "Among adults without ASCVD but with elevated Lp(a) or high-risk LPA genotypes, aspirin use did not confer a statistically significant cardiovascular benefit and was associated with numerically higher bleeding risk." (abstract, conclusions, passage verified)

  pubmedfull study (doi)